Current and emerging systemic treatment strategies for psoriasis - PubMed (original) (raw)
Review
Current and emerging systemic treatment strategies for psoriasis
Philip M Laws et al. Drugs. 2012.
Abstract
Psoriasis is a common chronic inflammatory disease of the skin that has a significant impact on quality of life. A small number of systemic therapies are well established in psoriasis management. These have immunosuppressive and/or anti-proliferative effects on the skin and immune system. As understanding of the pathogenesis of psoriasis has advanced over the last 2 decades, there has been clearer appreciation of the genetic, cellular and immunological components of disease expression, which has provided new insight into potential therapeutic targets, including the development of biological therapies. Biologics offer a unique opportunity to block or inhibit specific key components of psoriasis pathogenesis. The introduction of tumour necrosis factor (TNF).α and interleukin (IL)-12/-23 inhibitors has resulted in remarkable clinical responses in patients with severe psoriasis and has led to the development of a range of other cytokine modulators currently undergoing investigation. More recently, research in keratinocyte biology and immune cell function, particularly intracellular signalling, has afforded additional opportunities to develop a range of small-molecule oral preparations that may prove effective in disease control. This paper reviews current and emerging systemic treatments in the management of psoriasis.
Similar articles
- Developments in systemic immunomodulatory therapy for psoriasis.
Berger EM, Gottlieb AB. Berger EM, et al. Curr Opin Pharmacol. 2007 Aug;7(4):434-44. doi: 10.1016/j.coph.2007.06.002. Epub 2007 Jul 12. Curr Opin Pharmacol. 2007. PMID: 17627886 Review. - Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
Campanati A, Molinelli E, Brisigotti V, Offidani A. Campanati A, et al. Curr Pharm Biotechnol. 2017;18(12):945-963. doi: 10.2174/1389201019666180209121804. Curr Pharm Biotechnol. 2017. PMID: 29424306 Review. - The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S. Ten Bergen LL, et al. Scand J Immunol. 2020 Oct;92(4):e12946. doi: 10.1111/sji.12946. Scand J Immunol. 2020. PMID: 32697374 Review. - Could anti IL12/23 therapy replace anti-TNF biologics?
Ionescu MA, Lipozencić J. Ionescu MA, et al. Acta Dermatovenerol Croat. 2009;17(3):166-9. Acta Dermatovenerol Croat. 2009. PMID: 19818214 Review. - Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows.
Caiazzo G, Fabbrocini G, Di Caprio R, Raimondo A, Scala E, Balato N, Balato A. Caiazzo G, et al. Front Immunol. 2018 Aug 13;9:1668. doi: 10.3389/fimmu.2018.01668. eCollection 2018. Front Immunol. 2018. PMID: 30150978 Free PMC article. Review.
Cited by
- Non-Invasive Assessment of Skin Surface Proteins of Psoriasis Vulgaris Patients in Response to Biological Therapy.
Orro K, Salk K, Merkulova A, Abram K, Karelson M, Traks T, Neuman T, Spee P, Kingo K. Orro K, et al. Int J Mol Sci. 2023 Nov 13;24(22):16248. doi: 10.3390/ijms242216248. Int J Mol Sci. 2023. PMID: 38003437 Free PMC article. - Assessment of soluble skin surface protein levels for monitoring psoriasis vulgaris in adult psoriasis patients using non-invasive transdermal analysis patch: A pilot study.
Orro K, Salk K, Abram K, Arshavskaja J, Meikas A, Karelson M, Neuman T, Kingo K, Spee P. Orro K, et al. Front Med (Lausanne). 2023 Mar 2;10:1072160. doi: 10.3389/fmed.2023.1072160. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36936209 Free PMC article. - Nanodelivery Strategies for Skin Diseases with Barrier Impairment: Focusing on Ceramides and Glucocorticoids.
Almeida C, Filipe P, Rosado C, Pereira-Leite C. Almeida C, et al. Nanomaterials (Basel). 2022 Jan 15;12(2):275. doi: 10.3390/nano12020275. Nanomaterials (Basel). 2022. PMID: 35055292 Free PMC article. Review. - Olive Oil Based Methotrexate Loaded Topical Nanoemulsion Gel for the Treatment of Imiquimod Induced Psoriasis-like Skin Inflammation in an Animal Model.
Rashid SA, Bashir S, Naseem F, Farid A, Rather IA, Hakeem KR. Rashid SA, et al. Biology (Basel). 2021 Oct 31;10(11):1121. doi: 10.3390/biology10111121. Biology (Basel). 2021. PMID: 34827114 Free PMC article. - Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis.
Shah BJ, Mistry D, Chaudhary N, Shah S. Shah BJ, et al. Indian Dermatol Online J. 2020 Jan 13;11(1):51-57. doi: 10.4103/idoj.IDOJ_169_19. eCollection 2020 Jan-Feb. Indian Dermatol Online J. 2020. PMID: 32055509 Free PMC article.
References
- J Invest Dermatol. 2003 Dec;121(6):1383-8 - PubMed
- Med Res Rev. 2005 Mar;25(2):229-44 - PubMed
- J Eur Acad Dermatol Venereol. 2009 Oct;23 Suppl 2:1-70 - PubMed
- Joint Bone Spine. 2010 Dec;77(6):626-7 - PubMed
- Arch Dermatol. 1997 Jun;133(6):711-5 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials